Clearsight Advises SmartAnalyst in its Acquisition by UDG Healthcare plc

Clearsight Advisors, Inc. (“Clearsight”) is pleased to announce another successful transaction in its market-leading Healthcare Consulting Practice. Clearsight served as the exclusive strategic and financial advisor to SmartAnalyst in its acquisition by UDG Healthcare plc (LON: UDG) (“UDG”). This transaction further emphasizes Clearsight’s position as the leader in advising high-end consulting firms serving the life sciences and broader healthcare industries.

“Clearsight Advisors was selected as the exclusive representative of SmartAnalyst because of their focus and knowledge on the life sciences domain. Clearsight’s experience with this particular facet of healthcare technology made them a natural fit for our needs and we are thrilled that they were able to help take our business to the next level with UDG Healthcare,” commented Manu Bammi, Co-Founder and CEO of SmartAnalyst.

SmartAnalyst is a US-based strategic consulting and analytics business focused on the pharmaceutical and biotech sector. The company was founded in 2001 and has 135 employees based across operations in New York, London and, India. SmartAnalyst provides strategic consulting services to leading global pharmaceutical and biotech companies to support disease, asset, and portfolio level decisions.

UDG is a leading provider of commercial, clinical, communications, and packaging services to the healthcare industry. UDG’s Ashfield division is a global leader in commercialization services for the pharmaceutical and healthcare industry, operating across three areas of activity: advisory, communication, commercial & clinical services.

The acquisition of SmartAnalyst is in line with Ashfield’s strategy to expand its advisory service proposition for its healthcare clients and follows the acquisitions of STEM in October 2016 and Vynamic in July 2017.

“Manu and the SmartAnalyst team built a highly-respected consulting and information services provider for pharmaceutical and bio-pharmaceutical companies. Their work and depth of knowledge in the sector is a critical contributor to their clients in identifying and developing the next generation of innovative therapies. These capabilities are a natural fit for UDG Healthcare’s expanding portfolio of services and we are proud to have been able to work closely with Manu and the Board to help achieve SmartAnalyst’s strategic and financial goals,” commented Joel Kallett, Co-Founder and Managing Director at Clearsight Advisors.